These data indicate that survey participants generally accurately self-reported which drug type they were using, although EHR data reported a higher fraction of users relying on compounded versions of the medications (18.9% in EHR versus 13.5% in self-report for semaglutide, and 6.1% versus 4.8% for tirzepatide)
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Prez M, et al
The findings were reported in the paper, Relative effects of genetically proxied glucagonlike peptide1 receptor agonism on muscle and fat mass: A Mendelian randomization study, published in Diabetes, Obesity and Metabolism
If you are not obese, can you still take Semaglutide GLP-1
It is unfortunate that insurance will not cover it
was supported by an International Atherosclerosis Society Fellowship